OncoC4 closes nearly $50 million Series B financing

US clinical-stage biotech OncoC4 revealed it has closed a Series B financing round of nearly $50 million, led by GBA Fund, and supported by additional capital from the company's co-founders and existing investors, including HM Capital, 3E Bioventures Capital and Kaitai Capital.

Rockville, Maryland-based OncoC4 was founded in 2020 by two renowned immunologists and serial entrepreneurs, Dr Yang Liu and Dr Pan Zheng. By leveraging deep expertise in immuno-oncology and translational medicine, the company has built a broad pipeline of innovative therapies with first-in-class or best-in-class potential. The proceeds from the Series B financing will primarily be used to support the advancement of the clinical development of the company's pipeline programs.

In March 2023, OncoC4 announced a strategic collaboration with Germany’s BioNTech (Nasdaq: BNTX) to co-develop and commercialize ONC-392 in multiple solid tumor indications. OncoC4 received $200 million upfront and is eligible to receive development, regulatory, and commercial milestone payments in addition to double digit royalties. In addition, OncoC4 also has a pipeline of first-in-class and best-in-class assets targeting both novel and well validated